2型糖尿病治疗新药沙格列汀的药理及临床评价

Pharmacological and clinical evaluations of a new drug on treating type 2 diabetes:saxagliptin

二肽基肽酶(DPP-4)抑制剂沙格列汀是一种具有新型作用机制的2型糖尿病治疗药物,2009年7月31日,获美国FDA批准上市,2011年5月17日,在中国获得上市批准(商品名:安立泽)。研究证实,沙格列汀作为单药治疗或与二甲双胍的联合治疗,能有效改善血糖控制,没有明显的体重改变,发生低血糖的风险较低。现就其作用机制、药代动力学、临床研究及不良反应等做一综述。

The dipeptidyl peptidase-4 （DPP-4） inhibitor saxagliptin is a therapeutic drug with new action mechanisms for treating type 2 diabetes. It has been approved by U. S. FDA for marketing on 31 th July 2009, and approved in China on 17th May 2011. Saxagliptin has been demonstrated to effectively control blood glucose as monotherapy or as add-on therapy to metformin, not to significantly affect body weight, and to exhibit a low risk of hypoglycaemia. Here, the action mechanisms, pharmacokinetics, clinical studies and adverse reactions of saxagliptin were reviewed.